Literature DB >> 17371237

Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?

B Geering1, P R Cutillas, B Vanhaesebroeck.   

Abstract

Class IA PI3Ks (phosphoinositide 3-kinases) consist of a p110 catalytic subunit bound to one of five regulatory subunits, known as p85s. Under unstimulated conditions, p85 stabilizes the labile p110 protein, while inhibiting its catalytic activity. Recruitment of the p85-p110 complex to receptors and adaptor proteins via the p85 SH2 (Src homology 2) domains alleviates this inhibition, leading to PI3K activation and production of PIP(3) (phosphatidylinositol 3,4,5-trisphosphate). Four independent p85 KO (knockout) mouse lines have been generated. Remarkably, PI3K signalling in insulin-sensitive tissues of these mice is increased. The existence of p110-free p85 in insulin-responsive cells has been invoked to explain this observation. Such a monomeric p85 would compete with heterodimeric p85-p110 for pTyr (phosphotyrosine) recruitment, and thus repress PI3K activity. Reduction in the pool of p110-free p85 in p85 KO mice was thought to allow recruitment of functional heterodimeric p85-p110, leading to increased PI3K activity. However, recent results indicate that monomeric p85, like p110, is unstable in cells. Moreover, overexpressed free p85 does not necessarily compete with heterodimeric p85-p110 for receptor binding. Using a variety of approaches, we have observed a 1:1 ratio between the p85 and p110 subunits in murine cell lines and primary tissues. Alternative models to explain the increase in PI3K signalling in insulin-responsive cells of p85 KO mice, based on possible effects of p85 deletion on phosphatases acting on PIP(3), are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371237     DOI: 10.1042/BST0350199

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  25 in total

Review 1.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

2.  p85α mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response.

Authors:  L Song; M Gao; W Dong; M Hu; J Li; X Shi; Y Hao; Y Li; C Huang
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

3.  Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Authors:  Yash Chhabra; Caroline N Nelson; Monika Plescher; Johanna L Barclay; Aaron G Smith; Sof Andrikopoulos; Salvatore Mangiafico; David J Waxman; Andrew J Brooks; Michael J Waters
Journal:  FASEB J       Date:  2019-02-19       Impact factor: 5.191

4.  Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.

Authors:  Snehal M Gaikwad; Pritha Ray
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Uncovering the PI3Ksome: phosphoinositide 3-kinases and counteracting PTEN form a signaling complex with intrinsic regulatory properties.

Authors:  Claire Conche; Karsten Sauer
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

Review 6.  Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.

Authors:  Sarah E M Herman; Amy J Johnson
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

Review 7.  Insulin signaling meets mitochondria in metabolism.

Authors:  Zhiyong Cheng; Yolanda Tseng; Morris F White
Journal:  Trends Endocrinol Metab       Date:  2010-07-16       Impact factor: 12.015

8.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

9.  H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.

Authors:  A Chakrabarty; B N Rexer; S E Wang; R S Cook; J A Engelman; C L Arteaga
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

10.  Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.

Authors:  Slavé Petrovski; Roberta E Parrott; Joseph L Roberts; Hongxiang Huang; Jialong Yang; Balachandra Gorentla; Talal Mousallem; Endi Wang; Martin Armstrong; Duncan McHale; Nancie J MacIver; David B Goldstein; Xiao-Ping Zhong; Rebecca H Buckley
Journal:  J Clin Immunol       Date:  2016-04-13       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.